Marker Therapeutics Inc (MRKR)

[Rkmatters]

The combo trial is but a month old. It is the first time they are testing in patients with tumors.

The final efficacy results of the prior Phase I trial has yet to be reported. And it is time to disease recurrence as a final endpoint. Beyond that, your post on efficacy results is such poor comparison. Essentially they were treating patients who technically had no tumors but residual cancer cells/disease who were a high likelihood to recur. The patients in their trial were out of treatment options and significant extension will be highly valuable. Based on their Phase I primary endpoint TPIV received FAST TRACK in Ovarian, whereas IMGN did not. To suggest it isn't as good as IMGN is bizarre. It's likely better.